The 2nd Life Sciences Sector Deal and the NHS 10 Year Plan
Overview
Brexit uncertainty isn’t going away any time soon – but it’s important to remember that the UK government has already set out two plans for the future shape of the country’s healthcare industry: the second Life Sciences Sector Deal and the long-term plan for the NHS.
With these two plans in place there are plenty of opportunities for the industry and the government to work together to keep the UK at the top of the international life sciences sector – and perhaps reach even greater heights.
This pharmaphorum webinar, held in partnership with IQVIA, and following on from their recent white paper on the topic, analysed the current and future landscape for UK life sciences as well as what steps have been taken so far to boost the sector.
Panellists from across the industry looked at the challenges presented by the current situation with Brexit and how the 10-Year Plan and the Sector Deal 2 (or 2018) play into this. They discussed the positive steps taken by the government to prepare NHS innovation for a radically different future and make sure the UK remains an attractive location for ongoing inward investment from global pharma.
Focus
The webinar was held on Thursday 7th February from 12:45—13:45 GMT and took an in-depth look at what’s in store for the UK Industry in the coming years. The audience also had a chance to interact with the panel to learn about their views on how companies can harness the opportunities presented by the government’s two plans to thrive in the future UK market.
Topics covered included:
- Highlights of the 10-Year Plan and the second Sector Deal
- Progress with the current Life Sciences Industrial Strategy, the Sector Deal and plans for 2019
- The NHS innovation uptake agenda
- Maintaining UK attractiveness for inward global pharma and biotech investment
To view the webinar on demand, please click here or on the button above or below.
Our Panel
Dr Keri Torney, Deputy Director, Life Sciences, NHS EnglandKeri is the Deputy Director of Life Sciences in the Research, Innovation, and Life Sciences group, which lies within the Strategy and Innovation Directorate in NHS England. Her role is to build the pipeline of innovations and to get faster adoption of proven innovations into the NHS. This remit covers the Accelerated Access Collaborative, Innovation, Technology and Payment programme, and Clinical Entrepreneurs programme. She works closely with the Office of Life Sciences to support implementation of the Life Sciences Industrial Strategy and sector deals.
A civil servant by background, Keri has developed national government policy, negotiated at EU and international level, worked with local government, and led cross-sector programmes. Prior to this role, Keri was Deputy Director of Strategy at Public Health England, and was then seconded for a year at Healthy London Partnerships. Keri has a PhD in molecular biology from the University of Cambridge.
Dr Suki Balendra, Senior Policy Manager, Office of Life Sciences
Dr Suki Balendra is a senior policy manager in the Office of Life Sciences with a focus on the UK clinical trials sector and government policy.
Suki started her career in the biotechnology industry at Abbott Diagnostics Ltd as a team leader in a manufacturing facility. Within a Good Manufacturing practice environment, she worked on a number of operational projects to improve efficiency, cost and reproducibility.
Suki then moved into the clinical research field and began her career in this area at Imperial College. For a number of years, she managed the national diabetes commercial and academic research portfolio for the National Institute of Health Research (NIHR) under Professor Desmond Johnston and Professor Nish Chaturvedi. She managed several projects with diabetes charities and funders to promote and develop diabetes research.
Suki joined the NHS in 2015 as Senior Industry Operations Manager for the clinical research network in North West London. She has significant experience in the implementation of health policy both at a local and national level.
Suki has a degree in biochemistry and PhD from the University of Warwick in protein biochemistry. Suki is accredited to black belt in Lean Six Sigma.
Erik Nordkamp, GM UK and Cluster lead Europe/Australia/New Zealand for Pfizer’s Upjohn Division and President of the ABPI
Erik Nordkamp is currently the GM UK and Cluster lead Europe/Australia/New Zealand for Pfizer’s Upjohn Division and President of the ABPI (Association of British Pharmaceutical Industry). He was UK Managing Director at Pfizer from Feb 2015 until Dec 2018. During his tenure as UK MD, Erik has also been Chair of the UK APG (American Pharmaceutical Group) from June 2016 until July 2018, and a Non-Executive Director at King’s College Hospital Trust from Jan 2016 until July 2018.
Erik Nordkamp joined Pfizer in 2010 as Head of Strategy Primary Care Europe/ Canada and served as Pfizer President and Managing Director Greece, Cyprus and Malta from Aug 2012 to Feb 2015. During his time in Greece, Erik also served as President of PhRMA Innovation Forum, where he led the transformation of the forum, positioning it as the main representative body for the innovative pharmaceutical industry in Greece.
Prior to joining Pfizer, Erik worked at Eli Lilly for over 10 years holding a number of senior regional and local positions across the business in the UK and Germany and 4 years as a management consultant for Arthur D.Little in Brussels, Belgium.
Erik is a Dutch national who graduated from Nijmegen University (Netherlands) with a Health Sciences degree. He also holds a European Master in Environmental Management from Varese University (Italy) and a MBA from Erasmus University (Netherlands).
Erik is fluent in Dutch (native language), English, German, speaks conversational French and has foundational knowledge of Greek.
Angela McFarlane, Market Development Director, IQVIA
Angela is Market Development Director for IQVIA, a human data sciences company formed through the 2016 merger of IMS Health and Quintiles. She works with Government, the NHS, the Pharmaceutical Industry and Patient Organisations on pioneering collaborations that will improve NHS patient access to medicines. She has over ten years’ experience in the commercialisation of rare disease medicines. Angela’s passion is working on initiatives that ensure grows post-Brexit as a priority country for inward investment in clinical research, real world evidence studies and new medicines launches. Angela founded and sold her own Market Access company to IMS Health in 2013; prior to this she was marketing director of a managed care hospital in Manchester, preceded by working for BMS and MSD in marketing. In 2018, she was nominated by Pharmaceutical Marketing Europe as one of the 30 most influential women in UK Healthcare.
Moderated by Paul Tunnah, CEO, pharmaphorum
Paul Tunnah is CEO and Founder of pharmaphorum media, which facilitates productive engagement for pharma, bringing healthcare together to drive medical innovation. It combines industry-leading content and social media engagement services with the globally recognised news, information and insight portal pharmaphorum.com, working with pharmaceutical companies, service providers and broader healthcare organisations to help communicate their thought leadership and connect them with relevant stakeholders.
* When you click to register for this webinar you will be taken to a website run by BrightTalk who host the webinar and gather your registration data.
This data may then be passed to pharmaphorum media limited, and in turn passed to the company(ies) we are partnering with to bring you the webinar. This data may be used by us and them for occasional marketing purposes. It will not be shared with any further third parties.
By clicking to register for this webinar you give consent for any data you provide to be used in this way.
If at any point you no longer wish to be contacted based on the information you provide during the registration for this webinar, please send an email to info@pharmaphorum.com requesting that your information is deleted in accordance with the General Data Protection Regulation.
